

telefónica no lo protegen. Su respuesta por escrito tiene que estar en formato legal correcto si desea que procesen su caso en la corte. Es posible que haya un formulario que usted pueda usar para su respuesta. Puede encontrar estos formularios de la corte y más información en el Centro de Ayuda de las Cortes de California (www.sucorte.ca.gov), en la biblioteca de leyes del condado o en la corte que le quede más cerca. Si no puede pagar la cuota de presentación, pida al secretario de la corte que le dé un formulario de exención de pago de cuotas. Si no presenta su respuesta a tiempo, puede perder el caso por incumplimiento y la corte le podrá quitar su sueldo, dinero y bienes sin más advertencia.

Hay otros requisitos legales. Es recomendable que llame a un abogado inmediatamente. Si no conoce a un abogado, puede llamar a un servicio de remisión a abogados. Si no puede pagar a un abogado, es posible que cumpla con los requisitos para obtener servicios legales gratuitos de un programa de servicios legales sin fines de lucro. Puede encontrar estos grupos sin fines de lucro en el sitio web de California

Legal Services (www.lawhelpcalifornia.org), en el Centro de Ayuda de las Cortes de California (www.sucorte.ca.gov) o poniéndose en contacto con la corte o el colegio de abogados locales. AVISO: Por ley, la corte tiene derecho a reclamar las cuotas y los costos extensos por imponer un gravamen sobre cualquier recuperación de \$10,000 o más de valor recibida mediante un acuerdo o una concesión de arbitraje en un caso de derecho civil. Tiene que pagar el gravamen de la corte antes de que la corte pueda desear el caso.

The name and address of the court is:
Superior Court of California, County of San Diego,
North County Branch
325 S. Melrose
Vista, CA 92081

The name, address, and telephone number of plaintiff's attorney, or plaintiff without an attorney, is: (El nombre, la dirección y el número de teléfono del abogado del demandante, o del demandante que no tiene abogado, es):
THOMAS J. ROTERT ATTORNEY AT LAW

Thomas J. Rotert (171056)
1083 Vine Street, #357, Healdsburg, CA 95448
Tel. (310) 713-0104
Electronically Filed, Superior Court of California, County of San Diego, 9/23/2025 by Clerk of the Superior Court, C. Franssen, Deputy Clerk

NOTICE TO THE PERSON SERVED: You are served
STATEMENT OF DAMAGES
(Personal Injury or Wrongful Death)
CASE NUMBER: 25CU051079N

ATTORNEY OR PARTY WITHOUT ATTORNEY
Thomas J. Rotert (SBN 17106)
Attorney at Law
1083 Vine Street, #357, Healdsburg, CA 95448
jtrotert@gmail.com
Tel: 310-713-0104

ATTORNEY FOR: Sleeveless Suits, LLC
SUPERIOR COURT OF CALIFORNIA, COUNTY OF SAN DIEGO

Street Address: 325 S. Melrose Dr.
City and Zip Code: Vista, CA 92081
Branch Name: North County

PLAINTIFF: Sleeveless Suits, LLC
DEFENDANT: Jeff Clark, et al.
To Venture Fit, LLC, a Nevada limited liability company:
Plaintiff Sleeveless Suits, LLC seeks damages in the above-entitled action, as follows:

- General damages: Amount to be proven at trial.
- Special damages: Amount to be proven at trial.
- Punitive damages: Plaintiff reserves the right to seek punitive damages in an amount to be determined.

\$500,000.00 when pursuing a judgment in the suit filed against you.
Date: June 2, 2026
/s/ Thomas J. Rotert
Pub Dates: 7/06, 7/13, 7/20, 7/27/2026

SAN DIEGO BUSINESS JOURNAL

4909 Murphy Canyon Road, Suite 200, San Diego, CA 92123
Phone: 858-277-6359 | Fax: 858-277-6398 | www.sdbj.com

PUBLISHER

KEVIN LEAP | k leap@sdbj.com
c. (619) 459-8582

ASSOCIATE PUBLISHER

DALE GANZOW | d ganzow@sdbj.com
c. (760) 585-6105

PUBLISHER EMERITUS

ARMON MILLS | armon.mills@gmail.com

CONTROLLER

JASON SEAL | j seal@sdbj.com

ACCOUNT EXECUTIVES

JENNIE BREISTER | j breister@sdbj.com
c. (619) 990-0475
MICHAEL DREWRY | mdrewry@sdbj.com
c. (858) 354-4657
JASON GIBB | j gibb@sdbj.com
c. (858) 705-0428
BRIAN MUSICK | b musick@sdbj.com
o. (858) 277-6359 x 3109 | c. (858) 922-0492

EDITOR-IN-CHIEF

JEFF CLEMETSON | j clemetson@sdbj.com
o. (858) 277-6359 x 3140 | c. (925) 984-1414

MANAGING EDITOR

BRAD GRAVES | bradg@sdbj.com
o. (858) 277-6359 x 3112 | c. (619) 366-6627

REPORTERS

MADISON GEERING | m geering@sdbj.com
(619) 772-1746
RAY HUARD | rhuard@sdbj.com
c. (858) 361-8082
ELI WALSH | ewalsh@sdbj.com
o. (858) 277-6359 x 3120

DIRECTOR OF OPERATIONS & EVENTS

SHELLEY BARRY | sbarr@sdbj.com
c. (858) 277-6778

DIRECTOR OF CREATIVE & PRODUCTION

DONALD BLOODWORTH | dbloodworth@sdbj.com
o. (858) 277-6359 x 3105 | c. (619) 861-0504

ADVERTISING GRAPHIC ARTIST

GABRIELA CORDOBA | g cordoba@sdbj.com
o. (858) 277-6359 x 3125

DIRECTOR OF BUSINESS OPERATIONS

ANN PEKKALA | a pekkala@sdbj.com
o. (858) 277-6359 x 3121

ASSISTANT DIRECTOR, OPERATIONS & EVENTS

HEIDI COURMOUSIS | h courmouis@sdbj.com
o. (858) 277-6359

CLASSIFIED / LEGAL ADVERTISING

ANN PEKKALA | sdbjlegals@sdbj.com
o. (858) 277-6359 x 3121



SDBJ GUEST COMMENTARY

California Should Own the Future of Longevity Medicine

■ By TONY MEDRANO

This year, California celebrated the 50th anniversary of Genentech's cloning of synthetic human insulin in a San Francisco lab, a massive feat in biotech innovation that now shapes how the world develops new medicines—from gene-editing to cancer therapies to COVID-19 vaccines.

California has become the world's dominant force in drug discovery, generating nearly \$400 billion in economic output and more FDA-approved drugs than any other state. However, as medicine designed with the help of AI rapidly transforms the biotech landscape, China is racing to own the next generation of biomedical innovation, aided by a faster regulatory environment. Increasingly, the advantage will belong to the country that can harness AI to discover and develop therapies fastest.

One of the most promising frontiers is peptide therapies. Peptides are naturally occurring molecules that help regulate essential biological processes, including tissue repair, inflammation control, muscle rebuilding, and metabolism. Today, AI-powered tools can analyze millions of peptide combinations in a matter of weeks—a process that once took years—accelerating the search for promising new therapies. As a result, researchers are moving potential treatments from discovery to clinical testing faster than ever.

The potential results are significant. Researchers found that the peptide Semaglutide reduced major cardiovascular events by 20% in over 17,000 patients while delivering sustained weight loss of roughly 10%. Given that heart disease and stroke cost the U.S. healthcare system \$223.2 billion annually, even modest treatment gains from peptide therapies could preserve billions in taxpayer resources and keep people out of nursing homes, off disability, and working longer. Similarly, chronic disease already costs the U.S. economy trillions in lost productivity every year. Biotech innovation can help change

that. However, many treatments remain stuck in early regulatory stages in the U.S. while other countries like China move ahead due to less regulatory friction.

China overtook the U.S. in total clinical trials in 2021 and now runs nearly 20% more each year. Approval timelines for first-in-human studies in China have fallen from over a year to a matter of months, giving Chinese companies a head start in bringing new therapies to market. Projections indicate 37% of large molecules will

energy supplies are becoming as essential to biotechnology as laboratory space and research universities. With California supplying 25% of all U.S. AI patents, hosting 33 of the nation's 50 leading private AI companies and deriving more than half of its economic output from healthcare, no state has more at stake in the race to lead in the next era of AI-driven medicine.

Finally, policymakers should strengthen collaboration between universities, research institutions, startups and established pharmaceutical companies. California already possesses an unmatched concentration of scientific talent and entrepreneurial expertise.

The challenge is not creating new government programs, but ensuring innovators can move quickly from breakthrough discovery to real-world deployment.

In the global race for AI-powered medicine, speed matters. The jurisdictions that enable responsible innovation will attract the investment, talent and research that define the next generation of medical advancement.

California invented the modern biotech industry. Letting it slip to Shanghai would be a generational mistake. ■

Tony Medrano is CEO and co-founder of LongevityPlan.AI, a platform that integrates performance and health data from athletes and uses proprietary digital twin technology, wearable data and biomarker data to deliver personalized performance optimization and longevity recommendations to clients. A U.S. Navy veteran, he has degrees from Harvard University and Columbia University as well as a JD/MBA from Stanford University.



Opinions expressed in SDBJ Guest Commentary do not necessarily reflect the views of the San Diego Business Journal and inclusion in this section does not constitute an endorsement. Guest commentaries are chosen for inclusion in this section based on their interest to the Community of Business. To submit a guest commentary for consideration, contact Editor-in-Chief Jeff Clemetson at jclemetson@sdbj.com.